Is Hba1C a poor yardstick for determining access to new T1D treatments in the real world
If you’ve ever looked at a clinical trials document for a type 1 treatment, you’ll nearly always spot two things. Reduction in Hba1C is a […]
Blog Posts
Rise of the Machines – Technology and “patient-driven” innovation in the treatment of diabetes #T1DRoM
On Saturday, if you didn’t know already, we ran a first for the UK. A day’s conference focusing on Diabetes Technology, and majoring on “Patient […]
The real cost of Time in Range – what it takes to replace Hba1C #ATTD2018
Anyone watching the Twitter feed for the Advanced Technologies and Treatments for Diabetes 2018 conference can’t fail to have noticed that, once again, the answer […]
As #WeAreNotWaiting solutions become more prevalent, how can healthcare professionals support users?
This is a question that has come up more frequently, as the prevalence of DIY systems becomes greater, and is seen even more commonly in […]
#SpareARose and #insulin4all – Highlighting the global healthcare dilemma
I’m one of the lucky people with T1D. What does that mean? It means that by virtue of solely my birth place, I have access […]
Designing by numbers? What have we learned from #WeAreNotWaiting about using APS systems?
What becomes very apparent when spending time in the #WeAreNotWaiting community is that commercial systems sometimes lack the imagination to understand what it is that […]
A day without a loop – trying to quantify the difference between Sugar Surfing and looping #WeAreNotWaiting
I’ve often mentioned that one of the biggest benefits of using a loop (of any sort) is that you get time back. I’ve also estimated […]
Enough is enough. I can’t go on…. Details of the EMA Submission Fiasp CSII study
Harking back to a disco classic, I have to put my hands up and admit that I’ve reached the end of my tether with Fiasp […]
Fiasp – going off-label. Being intentionally non-compliant!
Warning: What is discussed in this post is not recommended by the manufacturer and not aligned with the European Medicines Agency sign off for Fiasp. […]
Carb Ratio variation – a side effect of Fiasp or something else?
One of the things that I’ve previously noted is that I’ve seen a fair amount of variability in using Fiasp, both in insulin sensitivity and […]